SNSS:NASDAQ

Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The company has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.
SNSS:NASDAQ

Expert Comments:

Maxim Jacobs, Edison Investment Research (9/16/16)
"Sunesis released the first-in-human clinical data for SNS-062, its reversible non-covalent inhibitor of Bruton’s tyrosine kinase (BTK), at a scientific conference in September 2016. The results from the 32-subject, placebocontrolled Phase Ia trial validated the notion that a non-covalent inhibitor could have a viable pharmacokinetic and pharmacodynamic profile and showed a favorable safety profile. . .SNSS will be advancing the drug into a Phase Ib/II B-cell malignancy trial following these results."

Jefferson Research (9/9/16)
"Sunesis Pharmaceuticals Inc. is showing strong Earnings Quality, Cash Flow Quality and Operating Efficiency, and Valuation suggests a lower amount of price risk. . .the primary reason the overall rating improved during the last quarter was an improvement in the Operating Efficiency rating due to a high return on invested capital. Another factor in the upgraded overall rating was a stronger Earnings Quality rating. . .the valuation rating is based on both absolute and relative levels at SNSS compared to its peers within its sector. . .the valuation rating for SNSS remains a LOW RISK."

Zacks Equity Research (8/18/16)
"Sunesis Pharmaceuticals Inc. was a big mover last session, as its shares rose over 23% on the day. . .solid volume too with far more shares changing hands than in a normal session. Yesterday's rally breaks the recent trend for the company, as the stock is now trading above the volatile price range of 50 cents to 70 cents in the past one-month time frame. . .yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future."

Maxim Jacobs, Edison Investment Research (8/18/16)
"Sunesis Pharmaceuticals Inc.'s lead program is Qinprezo, a quinolone derivative for relapsed/refractory acute myeloid leukemia (AML) without the dose limiting cardiotoxicity of anthracyclines. . .Sunesis is also advancing its clinical asset, SNS-062, a novel non-covalent, oral BTK inhibitor . . .data from a Phase Ia study in healthy volunteers will be presented in September. A Phase I/IIa is expected to begin around year-end. Sunesis [has] a late-stage asset, potentially near European approval, as well as preclinical assets utilising promising targets, making it an attractive partner."

Maxim Jacobs, Edison Investment Research (8/3/16)
"Sunesis Pharmaceuticals Inc. met the EMA to clarify some of the questions submitted as part of the Qinprezo MAA process. . .the meeting with the EMA to clarify the questions asked in the process is not surprising given that previous approvals for AML in Europe have not been made on the typical intent-to-treat analyses due to the severity of the disease and lack of treatments. . .the company's BTK inhibitor SNS-062 is currently in a Phase Ia dose ranging study in healthy humans, and Sunesis has announced that initial results from the study will be reported at an ESH medical conference on 9-11 September 2016."

Maxim Jacobs, Edison Investment Research (6/23/16)
"Sunesis Pharmaceuticals Inc. is a pharmaceutical company developing small molecule oncology drugs. Its lead program is Qinprezo [for] relapsed/refractory acute myeloid leukemia. . .the company is also advancing its clinical asset, SNS-062, a novel, non-covalent, oral BTK inhibitor that may work in Imbruvica-relapsed and refractory patients. . .Sunesis is an oncology company with a late-stage asset, potentially near European approval, as well as preclinical assets utilizing promising targets, making it an attractive partner."

More Expert Comments

Experts Following This Company

Matthew Andrews, Equity Senior Analyst – Wells Fargo Securities
Mara Goldstein, Senior Analyst – Cantor Fitzgerald
Maxim Jacobs – Edison Investment Research
Alan Leong, CEO – BioWatch News
Hartaj Singh, Biotechnology Analyst – BTIG Research
George Zavoico, Senior Equity Analyst – JonesTrading

The information provided above is from analysts, newsletters, the company and other contributors.

Sunesis Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Totality of VALOR data shows compelling risk-benefit trade-off in disease with significant unmet need
 
Relapsed/refractory AML is a significant commercial opportunity with no approved agents
 
Company's kinase inhibitor pipeline is poised to progress to the clinic in 2015 and 2016